ArticleNature communications2025
Periodic asymmetric field enhances electrofusion of nanoscale lipid systems.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles as emerging platforms for modulating innate immune responses in sepsis-associated acute lung injury.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electrofusion is a widely used technique for inducing membrane merging in biological systems, with applications ranging from hybrid lipid architectures to therapeutic delivery. However, the direct application of conventional electrofusion to advanced nanoscale drug carriers, such as cell membrane hybrid LNPs (cLNPs), faces challenges due to diminished dielectric response and uncontrolled particle dynamics. To address these limitations, we report a periodic asymmetric field (PAF) strategy that combines microfluidic flow with periodic electric fields to enhance nanoscale electrofusion. We systemically investigate the underlying mechanisms using computational fluid dynamics simulations, and subsequently fabricate and optimize a PAF-guided microfluidic electrofusion device (PAF-MED) for the controlled synthesis of cLNPs. These PAF-MED-synthesized cLNPs demonstrate improved fusion efficiency, augmented targeting capability, and superior therapeutic efficacy in bleomycin-induced pulmonary fibrosis murine models. This approach represents a unique advancement in the nanoscale manipulation of drug carriers towards better bio-functionality and reproducibility beyond conventional capability of electrofusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.